Pharmacologic Properties of Directly Acting Antivirals (DAAs) for Hepatitis C

Information in this section is based on currently available data, including product monographs, published articles, conference abstracts and posted guidelines (as noted in the Reference section). However, given the rapid pace of developments in this therapeutic area, it is acknowledged that these tables are not all-inclusive. Therefore, please use caution whenever adding or modifying therapy, and consult a health care professional when possible. Readers are urged to check the website regularly for new information and updates.

NS3/4A Protease Inhibitors

Green Pills
Multi-colour Pills

NS5A Nucleotide Inhibitor

NS5B Nucleotide Inhibitor